Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema

Shannon Meledathu; Paul Kim Ho Chu; Tatyana Feldman; André Goy; Rachel K. Rosenstein

doi:10.1016/j.jdcr.2024.10.001

Related publications

Article2004

Bruton’s tyrosine kinase (Btk)—the critical tyrosine kinase in LPS signalling?

Caroline A. Jefferies, Luke O'neill

Immunology Letters

Article2021

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Chloe Pek Sang Tang, Professor Gregory Lip, Terry McCormack, Alexander R. Lyon, Peter Hillmen, Sunil Iyengar, Nicolás Martínez‐Calle, Nilima Parry‐Jones, Piers Patten, Anna Schuh, Renata Walewska

Article2007

Signaling by Toll-like Receptors 8 and 9 Requires Bruton's Tyrosine Kinase

Sarah Doyle, Caroline A. Jefferies, C. Feighery, Luke O'neill

Journal of Biological Chemistry

Article2015

Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer

Andrew J. Gunderson, Megan M. Kaneda, Takahiro Tsujikawa, Abraham V. Nguyen, Nesrine I. Affara, Brian Ruffell, Sara Gorjestani, Shannon M. Liudahl, Morgan Truitt, Peter Olson, Grace Kim, Douglas Hanahan, Margaret A. Tempero, Brett C. Sheppard, Bryan Irving, Betty Chang, Judith A. Varner, Lisa M. Coussens

Article2012

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

Koon-Guan Lee, Shengli Xu, Zi-Han Kang, Jianxin Huo, Mei Huang, Ding Xiang Liu, Osamu Takeuchi, Akira Shizuo, Kong‐Peng Lam

Proceedings of the National Academy of Sciences